Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BDSI Touts Pain Therapy Pipeline After Emezine "Not Approvable" Letter

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

BioDelivery Sciences International is touting the potential of its flagship analgesic pipeline and downplaying Emezine for severe nausea and vomiting after receiving a "not approvable" letter from FDA Feb. 28 for the latter treatment.

You may also be interested in...

BDSI BEMA fentanyl NDA in Q2’07

BioDelivery Sciences plans to submit an NDA for its BEMA fentanyl oral adhesive disc in the second quarter of 2007, the company says Sept. 20. The Morrissville, N.C. firm is targeting use in breakthrough pain and projects $250 mil. in peak sales (1Pharmaceutical Approvals Monthly March 2006, p. 19). On Sept. 26, BDSI announced that the Research Advisory Panel of California approved the restart of two Phase III protocols of the proprietary fentanyl formulation. BDSI received a "not approvable" letter Feb. 28 for its antiemetic Emezine (prochlorperazine) for use in severe nausea and vomiting and subsequently began highlighting its BEMA formulations, which include a long-acting analgesic and zolpidem (Sanofi-Aventis' Ambien and tentatively approved generics)...

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts